$ONCT
Oncternal Therapeutics Inc

2020 Q2 Form 10-Q Financial Statement

#000156459020022300 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $623.0K $578.0K $470.0K
YoY Change -7.01% 22.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.340M $2.630M $930.0K
YoY Change 44.44% 182.8% -65.43%
% of Gross Profit
Research & Development $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.158M $5.329M $2.828M
YoY Change -72.38% 88.44% -79.34%
Operating Profit -$5.535M -$4.751M -$2.358M
YoY Change -74.4% 101.48%
Interest Expense $0.00 $10.00K $50.00K
YoY Change -100.0% -80.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $13.00K $64.00K
YoY Change -100.0% -79.69% -50.77%
Pretax Income -$5.540M -$4.740M -$2.290M
YoY Change -75.75% 106.99% -83.11%
Income Tax
% Of Pretax Income
Net Earnings -$5.535M -$4.738M -$2.294M
YoY Change -75.77% 106.54% 53.86%
Net Earnings / Revenue -888.44% -819.72% -488.09%
Basic Earnings Per Share
Diluted Earnings Per Share -$341.1K -$308.6K -$622.3K
COMMON SHARES
Basic Shares Outstanding 15.39M 15.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.60M $16.00M $21.20M
YoY Change -41.75% -24.53% -33.96%
Cash & Equivalents $16.60M $16.02M $16.94M
Short-Term Investments $200.0K
Other Short-Term Assets $1.400M $500.0K $1.300M
YoY Change 0.0% -61.54% -38.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.00M $16.56M $22.50M
YoY Change -39.74% -26.38% -34.21%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $200.0K $0.00
YoY Change -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $1.047M
YoY Change 4.3%
Total Long-Term Assets $900.0K $1.201M $100.0K
YoY Change -12.79% 1101.0% -50.0%
TOTAL ASSETS
Total Short-Term Assets $18.00M $16.56M $22.50M
Total Long-Term Assets $900.0K $1.201M $100.0K
Total Assets $18.90M $17.77M $22.60M
YoY Change -38.84% -21.39% -34.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M $1.376M $600.0K
YoY Change -45.75% 129.33% -64.71%
Accrued Expenses $3.607M $2.778M $1.200M
YoY Change 41.45% 131.5% -84.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.000M $7.317M $1.800M
YoY Change 14.78% 306.5% -81.25%
LONG-TERM LIABILITIES
Long-Term Debt $300.0K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Liabilities $300.0K $100.0K $0.00
YoY Change 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.000M $7.317M $1.800M
Total Long-Term Liabilities $300.0K $100.0K $0.00
Total Liabilities $9.300M $7.400M $1.800M
YoY Change 16.25% 311.11% -81.25%
SHAREHOLDERS EQUITY
Retained Earnings -$75.80M -$70.31M
YoY Change 34.1%
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.598M $10.40M -$31.88M
YoY Change
Total Liabilities & Shareholders Equity $18.90M $17.77M $22.60M
YoY Change -38.84% -21.39% -34.3%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$5.535M -$4.738M -$2.294M
YoY Change -75.77% 106.54% 53.86%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.220M -$4.036M -$3.633M
YoY Change -32.37% 11.09% -67.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$80.00K
YoY Change -100.0% -100.0% -100.73%
Cash From Investing Activities $0.00 $0.00 -$79.00K
YoY Change -100.0% -100.0% -100.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.820M 4.000K 2.000K
YoY Change 100.0% -100.31%
NET CHANGE
Cash From Operating Activities -4.220M -4.036M -3.633M
Cash From Investing Activities 0.000 0.000 -79.00K
Cash From Financing Activities 4.820M 4.000K 2.000K
Net Change In Cash 600.0K -4.032M -3.710M
YoY Change -94.82% 8.68% 336.47%
FREE CASH FLOW
Cash From Operating Activities -$4.220M -$4.036M -$3.633M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15392000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12230 El Camino Real
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q1 dei City Area Code
CityAreaCode
858
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15392377
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
154000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1047000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
20787000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
736000
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2020Q1 dei Entity File Number
EntityFileNumber
000-50549
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 us-gaap Assets Current
AssetsCurrent
16564000
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
62-1715807
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
545000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20051000
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
434-1113
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
190000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16019000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1376000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2294000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
79869000
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65572000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21744000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15387000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15387000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80690000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
91000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14312000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Revenues
Revenues
470000
CY2019Q4 us-gaap Assets
Assets
21744000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7341000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2778000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7317000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
767000
CY2020Q1 us-gaap Revenues
Revenues
578000
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2696000
CY2019Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1896000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2731000
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 us-gaap Deferred Revenue
DeferredRevenue
3062000
CY2019Q4 us-gaap Deferred Revenue
DeferredRevenue
3640000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
932000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
2828000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2358000
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
47000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4738000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2294000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15355
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3676
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-4738000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70310000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Assets
Assets
17765000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15392000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
871000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
101000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10395000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17765000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2633000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
5329000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
15000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4751000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-31880000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20051000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-29631000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#8217;s preferred stock, preferred stock warrant liability and stock-based awards, and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
CY2019Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
87000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3039
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9097
CY2020Q1 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1339000
CY2019Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1206000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
824000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
825000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-2294000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
399000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39000
CY2020Q1 onct Noncash Lease Expense
NoncashLeaseExpense
36000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-90000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-158000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
336000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2422000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
455000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
264000
CY2020Q1 onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-36000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-578000
CY2019Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
639000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4036000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3633000
CY2019Q1 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
79000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4032000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3710000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20645000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16019000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16935000
CY2020Q1 us-gaap Stock Issued1
StockIssued1
415000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1268000
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
179000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q1 onct Adjustments To Additional Paid In Capital Vesting Related To Repurchase Liability Net
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToRepurchaseLiabilityNet
3000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
415000
CY2019Q1 onct Adjustments To Additional Paid In Capital Vesting Related To Repurchase Liability Net
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToRepurchaseLiabilityNet
4000
CY2020Q1 onct Warrants Liabilities
WarrantsLiabilities
0
CY2019Q4 onct Warrants Liabilities
WarrantsLiabilities
0
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
32000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
417000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
424000
CY2020Q1 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
20000
CY2019Q4 onct Accrued Unvested Share Liability
AccruedUnvestedShareLiability
24000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
124000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
41000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
165000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
154000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q1 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
20000
CY2019Q4 onct Liability For Unvested Cash Settled Share Based Payment Transactions
LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
24000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
35000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
5000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
30000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.894
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
399000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4000000
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2020Q1 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
841000
CY2020Q1 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
2168000
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4050000

Files In Submission

Name View Source Status
0001564590-20-022300-index-headers.html Edgar Link pending
0001564590-20-022300-index.html Edgar Link pending
0001564590-20-022300.txt Edgar Link pending
0001564590-20-022300-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
onct-10q_20200331.htm Edgar Link pending
onct-20200331.xml Edgar Link completed
onct-20200331.xsd Edgar Link pending
onct-20200331_cal.xml Edgar Link unprocessable
onct-20200331_def.xml Edgar Link unprocessable
onct-20200331_lab.xml Edgar Link unprocessable
onct-20200331_pre.xml Edgar Link unprocessable
onct-ex311_7.htm Edgar Link pending
onct-ex312_6.htm Edgar Link pending
onct-ex321_9.htm Edgar Link pending
onct-ex322_14.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending